Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 12/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.48 |
| ▸ | SMO | Q99835 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17600705 | 1.00 | LMNA (0.53) | LMNATP53HCRTR2HCRTR1TRPV1 | |
| SCHEMBL31245524 | 0.86 | HCRTR2 (0.49) | LMNATP53HCRTR2HCRTR1TRPV1 | |
| SCHEMBL21958015 | 0.86 | HCRTR2 (0.49) | LMNATP53HCRTR2HCRTR1TRPV1 | |
| SCHEMBL21958017 | 0.86 | HCRTR2 (0.49) | LMNATP53HCRTR2HCRTR1TRPV1 | |
| SCHEMBL23884615 | 0.82 | LMNA (0.49) | LMNATP53HCRTR2HCRTR1TRPV1 | |
| SCHEMBL23884862 | 0.82 | HCRTR2 (0.48) | LMNATP53HCRTR2HCRTR1TRPV1 | |
| SCHEMBL21957873 | 0.82 | LMNA (0.48) | LMNATP53HCRTR2HCRTR1TRPV1 | |
| SCHEMBL23884683 | 0.81 | HCRTR2 (0.47) | LMNATP53HCRTR2HCRTR1TRPV1 | |
| SCHEMBL7960177 | 0.81 | TDP1 (0.48) | HCRTR2HCRTR1RAB9APOLB | |
| SCHEMBL5909267 | 0.79 | KMT2A (0.53) | LMNAHCRTR2HCRTR1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053195-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-11053195-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| EP-2970196-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10450269-B1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10450269-B1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190202782-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20190202782-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20190010121-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOBLOGIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-01-10 | — | — | US | disclosed |
| US-20160083343-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | Global Blood Therapeutics, Inc (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083343-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | Global Blood Therapeutics, Inc (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083343-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | Global Blood Therapeutics, Inc (US) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450269-B1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | LMNA 818/4885TP53 2529/4885HCRTR2 4569/4885 |
| US-20160083343-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | LMNA 823/4885TP53 2488/4885HCRTR2 4571/4885 |
| US-11053195-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | LMNA 823/4885TP53 2488/4885HCRTR2 4571/4885 |
| US-20190202782-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | LMNA 823/4885TP53 2488/4885HCRTR2 4571/4885 |
| US-20190010121-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOBLOGIN | HBG2, HBG1, HBB | LMNA 722/4885TP53 3824/4885HCRTR2 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.